Log in

NASDAQ:HRTXHeron Therapeutics Competitors & Alternatives

$15.53
-0.51 (-3.18 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.32
Now: $15.53
$16.44
50-Day Range
$14.26
MA: $18.37
$21.01
52-Week Range
$9.60
Now: $15.53
$26.81
Volume2.28 million shs
Average Volume2.28 million shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.69

Competitors

Heron Therapeutics (NASDAQ:HRTX) Vs. UTHR, RETA, RARE, MRTX, ZLAB, and ARWR

Should you be buying HRTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Heron Therapeutics, including United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), and Arrowhead Pharmaceuticals (ARWR).

Heron Therapeutics (NASDAQ:HRTX) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Volatility & Risk

Heron Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Earnings and Valuation

This table compares Heron Therapeutics and United Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million9.64$-204,750,000.00($2.50)-6.21
United Therapeutics$1.45 billion3.66$-104,500,000.00($2.39)-50.35

United Therapeutics has higher revenue and earnings than Heron Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Heron Therapeutics and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-138.31%-56.85%-43.05%
United Therapeutics36.59%19.19%13.33%

Insider & Institutional Ownership

98.1% of United Therapeutics shares are owned by institutional investors. 12.6% of Heron Therapeutics shares are owned by company insiders. Comparatively, 10.9% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Heron Therapeutics and United Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01902.90
United Therapeutics11702.67

Heron Therapeutics presently has a consensus target price of $38.1111, indicating a potential upside of 145.40%. United Therapeutics has a consensus target price of $138.00, indicating a potential upside of 14.68%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than United Therapeutics.

Summary

United Therapeutics beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Volatility & Risk

Heron Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Heron Therapeutics and Reata Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01902.90
Reata Pharmaceuticals01802.89

Heron Therapeutics presently has a consensus target price of $38.1111, indicating a potential upside of 145.40%. Reata Pharmaceuticals has a consensus target price of $255.1111, indicating a potential upside of 61.62%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Reata Pharmaceuticals.

Insider & Institutional Ownership

67.3% of Reata Pharmaceuticals shares are owned by institutional investors. 12.6% of Heron Therapeutics shares are owned by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Heron Therapeutics and Reata Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million9.64$-204,750,000.00($2.50)-6.21
Reata Pharmaceuticals$26.52 million197.85$-290,170,000.00($9.54)-16.55

Heron Therapeutics has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Heron Therapeutics and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-138.31%-56.85%-43.05%
Reata Pharmaceuticals-1,542.06%-322.36%-65.04%

Summary

Heron Therapeutics beats Reata Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Heron Therapeutics (NASDAQ:HRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Ultragenyx Pharmaceutical and Heron Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
Heron Therapeutics01902.90

Ultragenyx Pharmaceutical presently has a consensus target price of $81.3571, indicating a potential downside of 5.44%. Heron Therapeutics has a consensus target price of $38.1111, indicating a potential upside of 145.40%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Insider and Institutional Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 12.6% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Heron Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million49.49$-402,730,000.00($7.36)-11.69
Heron Therapeutics$145.97 million9.64$-204,750,000.00($2.50)-6.21

Heron Therapeutics has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
Heron Therapeutics-138.31%-56.85%-43.05%

Summary

Heron Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 14 factors compared between the two stocks.

Mirati Therapeutics (NASDAQ:MRTX) and Heron Therapeutics (NASDAQ:HRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mirati Therapeutics and Heron Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics041002.71
Heron Therapeutics01902.90

Mirati Therapeutics presently has a consensus target price of $111.4615, indicating a potential downside of 4.73%. Heron Therapeutics has a consensus target price of $38.1111, indicating a potential upside of 145.40%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Mirati Therapeutics.

Valuation and Earnings

This table compares Mirati Therapeutics and Heron Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million1,528.58$-213,260,000.00($5.69)-20.56
Heron Therapeutics$145.97 million9.64$-204,750,000.00($2.50)-6.21

Heron Therapeutics has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mirati Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Profitability

This table compares Mirati Therapeutics and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati Therapeutics-10,983.84%-53.25%-48.92%
Heron Therapeutics-138.31%-56.85%-43.05%

Summary

Heron Therapeutics beats Mirati Therapeutics on 8 of the 12 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Heron Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Zai Lab's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million9.64$-204,750,000.00($2.50)-6.21
Zai Lab$12.98 million363.01$-195,070,000.00($3.03)-26.77

Zai Lab has lower revenue, but higher earnings than Heron Therapeutics. Zai Lab is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Heron Therapeutics and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01902.90
Zai Lab00703.00

Heron Therapeutics currently has a consensus price target of $38.1111, indicating a potential upside of 145.40%. Zai Lab has a consensus price target of $57.3080, indicating a potential downside of 29.34%. Given Heron Therapeutics' higher possible upside, equities research analysts clearly believe Heron Therapeutics is more favorable than Zai Lab.

Institutional & Insider Ownership

78.3% of Zai Lab shares are held by institutional investors. 12.6% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-138.31%-56.85%-43.05%
Zai LabN/AN/AN/A

Heron Therapeutics (NASDAQ:HRTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Heron Therapeutics and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-138.31%-56.85%-43.05%
Arrowhead Pharmaceuticals6.86%2.61%2.08%

Risk and Volatility

Heron Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.

Insider and Institutional Ownership

64.3% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 12.6% of Heron Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Heron Therapeutics and Arrowhead Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million9.64$-204,750,000.00($2.50)-6.21
Arrowhead Pharmaceuticals$168.80 million26.65$67.97 million$0.6964.06

Arrowhead Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Heron Therapeutics and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01902.90
Arrowhead Pharmaceuticals02802.80

Heron Therapeutics presently has a consensus price target of $38.1111, indicating a potential upside of 145.40%. Arrowhead Pharmaceuticals has a consensus price target of $62.00, indicating a potential upside of 40.27%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats Heron Therapeutics on 10 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
United Therapeutics logo
UTHR
United Therapeutics
1.7$120.33-0.6%$5.30 billion$1.45 billion10.04Analyst Downgrade
Insider Selling
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$157.85-2.5%$5.25 billion$26.52 million-16.04
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.5$86.04-1.6%$5.13 billion$103.71 million-11.71Analyst Report
Analyst Revision
Heavy News Reporting
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
0.9$116.99-0.5%$5.11 billion$3.34 million-18.03
Zai Lab logo
ZLAB
Zai Lab
1.1$81.10-1.7%$4.71 billion$12.98 million-26.77
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.4$44.20-0.1%$4.50 billion$168.80 million491.17Analyst Revision
Heavy News Reporting
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.2$84.08-2.6%$4.41 billion$1.11 billion64.68Analyst Report
Myokardia logo
MYOK
Myokardia
1.4$94.11-0.3%$4.39 billion$33.56 million-14.11Analyst Downgrade
Insider Selling
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.6$79.15-0.2%$4.29 billion$66.51 million-10.65Analyst Downgrade
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$23.52-0.3%$4.19 billion$114.62 million-9.01Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.3$71.20-1.7%$4.17 billionN/A-5.64
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$67.83-3.8%$4.13 billion$2.11 million-13.93Analyst Upgrade
Analyst Revision
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.55-0.0%$4.01 billion$182.24 million-11.96Analyst Upgrade
Insider Selling
Unusual Options Activity
Analyst Revision
GW Pharmaceuticals PLC- logo
GWPH
GW Pharmaceuticals PLC-
1.8$125.35-0.7%$3.89 billion$311.33 million127.91Analyst Report
Analyst Revision
Heavy News Reporting
FibroGen logo
FGEN
FibroGen
2.1$43.50-3.1%$3.88 billion$256.58 million-32.95
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$55.69-0.1%$3.84 billion$117.91 million-9.49Analyst Upgrade
Analyst Revision
HUTCHISON CHINA/S logo
HCM
HUTCHISON CHINA/S
1.0$28.53-3.2%$3.81 billion$204.89 million-35.66Analyst Downgrade
Analyst Revision
Heavy News Reporting
BBIO
BridgeBio Pharma
1.6$29.76-1.9%$3.61 billion$40.56 million-12.00Analyst Upgrade
Insider Selling
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$58.01-0.2%$3.59 billion$36.13 million-53.22Analyst Downgrade
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$53.00-2.6%$3.47 billion$306.98 million-10.62Insider Selling
Analyst Revision
Allakos logo
ALLK
Allakos
1.1$66.90-0.6%$3.26 billionN/A-33.62Analyst Downgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.10-1.0%$3.18 billion$806.43 million-9.77
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.5$56.71-2.6%$3.17 billion$25 million-12.57Heavy News Reporting
Alkermes logo
ALKS
Alkermes
1.1$19.59-0.9%$3.11 billion$1.17 billion-22.26
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
2.2$80.97-3.6%$3.00 billionN/A-31.63Analyst Report
Heavy News Reporting
Insmed logo
INSM
Insmed
1.5$29.57-1.3%$2.99 billion$136.47 million-10.49Analyst Revision
KRTX
Karuna Therapeutics
1.3$109.74-3.0%$2.87 billionN/A-0.75Analyst Downgrade
Insider Selling
Amarin logo
AMRN
Amarin
1.8$6.92-1.6%$2.67 billion$429.76 million-115.33Analyst Revision
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$67.45-0.1%$2.58 billion$644.77 million10.61
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$32.96-3.0%$2.49 billionN/A-5.25Analyst Report
Analyst Revision
Heavy News Reporting
Opko Health logo
OPK
Opko Health
1.7$3.54-3.1%$2.37 billion$901.90 million-7.38Analyst Downgrade
TPTX
Turning Point Therapeutics
1.2$64.35-0.2%$2.31 billionN/A-17.87
SAGE Therapeutics logo
SAGE
SAGE Therapeutics
1.6$43.01-0.8%$2.23 billion$6.87 million-3.45
IGMS
IGM Biosciences
1.5$72.39-0.6%$2.21 billionN/A-15.08Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$20.09-1.1%$2.21 billion$150,000.00-9.90
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$52.37-1.5%$2.21 billion$421.03 million-2,617.19Analyst Report
Insider Selling
Analyst Revision
Heavy News Reporting
Uniqure logo
QURE
Uniqure
1.7$45.54-1.5%$2.02 billion$7.28 million-15.13Analyst Upgrade
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.0$17.18-0.5%$1.97 billion$306.49 million19.52Analyst Downgrade
Heavy News Reporting
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$49.27-2.5%$1.90 billion$26.69 million-37.33Heavy News Reporting
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$25.67-3.7%$1.90 billion$23.90 million-15.19Analyst Downgrade
Xencor logo
XNCR
Xencor
1.4$32.82-2.7%$1.87 billion$156.70 million-30.67
Principia Biopharma logo
PRNB
Principia Biopharma
1.4$56.00-4.3%$1.85 billion$35.16 million-22.95Insider Selling
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.8$36.17-2.0%$1.82 billion$963.01 million13.01Analyst Downgrade
Heavy News Reporting
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$20.03-0.6%$1.80 billionN/A-5.94Analyst Downgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$111.64-0.2%$1.79 billion$120.28 million-32.45
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$15.56-2.5%$1.75 billion$320,000.00-11.88Analyst Downgrade
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$111.58-0.6%$1.72 billionN/A-16.38
ZNTL
Passage Bio
1.8$47.97-0.4%$1.72 billionN/A0.00
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.5$13.08-1.4%$1.70 billion$335 million-5.92Unusual Options Activity
IMAB
I-Mab
1.2$29.32-1.0%$1.67 billion$4.31 million-1.01
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.